This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $139.38, moving +1.62% from the previous trading session.
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
by Zacks Equity Research
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
by Zacks Equity Research
J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
by Zacks Equity Research
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for IWX
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Myovant Up on Successful Completion of Prostate Cancer Study
by Zacks Equity Research
Myovant's (MYOV) phase III study evaluating lead pipeline candidate, relugolix, in patients with advanced prostate cancer meets primary endpoint.
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Johnson & Johnson, Boeing and PetroChina
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Amazon, Johnson & Johnson, Boeing and PetroChina
US Equities Continue to March Steadily Higher
by David Borun
Positive developments in international trade and healthcare puch stocks to another round of new record highs.
4 Big Drugmakers to Bet on After a Great Earnings Season
by Kinjel Shah
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
by Zacks Equity Research
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Why Is Johnson & Johnson (JNJ) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3
by Zacks Equity Research
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J
AbbVie Eyes Approval for Imbruvica+Rituxan in First-Line CLL
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.
Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products
by Kinjel Shah
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%
by Zacks Equity Research
Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Theravance's (TBPH) third-quarter loss matches estimates while revenues miss the same in absence of product sales due to the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for IWX
Medical Products' Earnings Roster for Nov 5: BDX, ZBH & More
by Urmimala Biswas
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Strong Economic conditions and Low Interest Rates Send Stocks to New Record Highs
by David Borun
Recession fears and a possible end to trade disputes support increasing US equity prices
AbbVie (ABBV) Beats on Q3 Earnings & Sales, Tweaks EPS View
by Zacks Equity Research
AbbVie (ABBV) beats on both earnings and revenues in the third quarter. The company ups the lower end of its 2019 guidance for adjusted earnings per share.
Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates
by Kinjel Shah
Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results.
Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View
by Zacks Equity Research
Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.